KP1019, A New Redox-Active Anticancer Agent - Preclinical Development and Results of a Clinical Phase I Study in Tumor Patients
- Author(s)
- Christian Hartinger, Michael Jakupec, Stefanie Zorbas-Seifried, Michael Größl, Alexander Egger, Walter Berger, Haralabos Zorbas, Paul J. Dyson, Bernhard Keppler
- Abstract
The promising drug candidate indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)]
(KP1019) is the second Ru-based anticancer agent to enter clinical trials. In this review, which is an
update of a paper from 2006 (Hartinger et al., J. Inorg. Biochem. 2006, 100, 891¿904), the experimental
evidencefortheproposedmodeofactionofthiscoordinationcompoundisdiscussed,includingtransport
into the cell via the transferrin cycle and activation by reduction. The results of the early clinical
development of KP1019 are summarized in which five out of six evaluated patients experienced disease
stabilization with no severe side effects.
- Organisation(s)
- Department of Inorganic Chemistry
- External organisation(s)
- Max-Planck-Institut für Chemie (Otto-Hahn-Institut), Medizinische Universität Wien, Ludwig-Maximilians-Universität München, École polytechnique fédérale de Lausanne
- Journal
- Chemistry & Biodiversity
- Volume
- 5
- Pages
- 2140-2155
- No. of pages
- 16
- ISSN
- 1612-1872
- Publication date
- 2008
- Peer reviewed
- Yes
- Austrian Fields of Science 2012
- 104003 Inorganic chemistry, 104002 Analytical chemistry, 301114 Cell biology
- Portal url
- https://ucrisportal.univie.ac.at/en/publications/b466ba1c-f2cd-4db2-9209-9cce5e2d442b